The Commission leads and coordinates a number of programs that support the objectives of the National Antimicrobial Resistance Strategy.

Healthcare Associated Infection (HAI) Prevention Program and Antimicrobial Stewardship Initiative

The HAI Prevention Program aims to build on facility and jurisdictional initiatives to develop a national approach to reducing HAI by identifying and addressing systemic problems and gaps, and ensuring comprehensive actions are undertaken in a nationally coordinated way by leaders and decision makers in both public and private health care sectors. The National Antimicrobial Stewardship Initiative is a key component of the HAI program and aims to support activities that optimise antimicrobial use, improve patient outcomes and reduce the incidence of antimicrobial resistance in Australian hospitals.

The Antimicrobial Stewardship Clinical Care Standard

The Antimicrobial Stewardship (AMS) Clinical Care Standard aims to ensure that a patient with a bacterial infection receives optimal treatment with antibiotics –  the right antibiotic to treat their condition, the right dose, by the right route, at the right time and for the right duration based on accurate assessment and timely review.

Antimicrobial Use and Resistance in Australia (AURA) project

The Australian Government Department of Health has provided funding to the Australian Commission on Safety and Quality in Health Care to develop a national surveillance system for AU and AMR: this is the Antimicrobial Use and Resistance in Australia (AURA) project. The AURA project is vital to Australia’s efforts to prevent and contain AMR as it will provide information needed to understand where and when specific threats emerge, as well as guiding efforts to mitigate the risk of AMR at a local, jurisdictional and national

Recommendations for the control of carbapenemase-producing Enterobacteriaceae (CPE): A guide for acute care health facilities

Gram-negative bacteria – including Enterobacteriaceae – that are resistant to most, or all, types of antibiotics have emerged as a significant global public health threat. Resistance to carbapenem antibiotics is of particular concern. Multi drug resistant gram-negative bacteria, including carbapenemase producing Enterobacteriaceae (CPE), place Australian patients at greater risk of potentially untreatable infection and increased mortality.

 

The Commission worked in partnership with the Australasian Society of Infectious Diseases, Australasian College of Infection Prevention and Control, Public Health Laboratory Network and Australasian Society of Antimicrobials to update the recommendations for the management and testing of patients with CPE.